Targeting molecular descriptors of pancreatic embryogenesis may be relevant to treating
pancreatic ductal adenocarcinoma (PDAC). This strategy recognizes the cancer stem cell …

Cancer stemness is associated with high malignancy and low differentiation, as well as
therapeutic resistance of tumors including pancreatic ductal adenocarcinoma (PDAC) …

1 School of Pharmaceutical Sciences and International Collaborative Center on Growth
Factor Research, Wenzhou Medical University, Wenzhou, China, 2 Institute of Life Sciences …

All mature pancreatic cell types arise from organ-specific multipotent progenitor cells.
Although previous studies have identified cell-intrinsic and-extrinsic cues for progenitor cell …

Background: Fibroblast growth factor receptor (FGFR) signalling has been implicated in
pancreas carcinogenesis. We investigated the effect of FGFR inhibition in pancreatic cancer …

Pancreatic adenocarcinoma (PDAC) is projected to become the second leading cause of
cancer deaths by 2030, and its five-year survival is 12%(Rahib et al., 2014; Siegel, Miller …

Objectives: Here we describe the durable clinical outcomes of four FGFR2 fusion positive
pancreatic cancer patients treated with FGFR inhibitors as well as a pancreatic specific …

Pancreatic cancer is the fourth leading cause of cancer-related death in the United States. It
is characterized by a dense desmoplastic stroma that is thought to limit drug delivery and to …

The fibroblast growth factor receptor (FGFR) family plays crucial roles in development, tissue
repair, and malignant tumors. FGFR-1,-2, and-3 each exist in two isoforms, IIIb and IIIc, due …

Pancreatic cancer is characterised by desmoplasia, driven by activated pancreatic stellate
cells (PSC s). Over‐expression of FGF s and their receptors is a feature of pancreatic cancer …